| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.28963 |
| P8608 | Fatcat ID | release_nm5sbusgqbgllkqr35tqweooti |
| P932 | PMC publication ID | 4270372 |
| P698 | PubMed publication ID | 24817381 |
| P5875 | ResearchGate publication ID | 262228699 |
| P50 | author | Nubia Muñoz | Q25410302 |
| Xavier Castellsagué | Q28919226 | ||
| Jorge Salmerón | Q58664238 | ||
| Laia Alemany Perez | Q77862279 | ||
| Antonio L Cubilla | Q89834262 | ||
| Nuria Guimera | Q90822631 | ||
| Isabel Alvarado-Cabrero | Q91089349 | ||
| Robert Jach | Q91290480 | ||
| Brenda Hernandez | Q100388190 | ||
| Marc T Goodman | Q114258099 | ||
| Hai-Rim Shin | Q114302734 | ||
| Edyta C Pirog | Q114454408 | ||
| Belen Lloveras | Q114454409 | ||
| Elena Kasamatsu | Q114454410 | ||
| Leopoldo Tinoco | Q114454411 | ||
| Daan T Geraets | Q114454412 | ||
| Christine Clavel | Q114454413 | ||
| Cathy Ndiaye | Q114454414 | ||
| Michael Pawlita | Q37242255 | ||
| Silvia de Sanjosé | Q47367042 | ||
| Ana Felix | Q47504423 | ||
| Jan Laco | Q51722221 | ||
| Omar Clavero | Q56378167 | ||
| Ignacio G Bravo | Q56581246 | ||
| Beatriz Quirós | Q56863156 | ||
| P2093 | author name string | Charles F Lynch | |
| Vaclav Mandys | |||
| Mario Poljak | |||
| Francesc X Bosch | |||
| Gustavo Hernandez-Suarez | |||
| Josep Verge | |||
| Maëlle Saunier | |||
| JoEllen Klaustermeier | |||
| HPV VVAP Study Group | |||
| William G Quint | |||
| P2860 | cites work | Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio | Q24797650 |
| The increasing incidence of anal cancer: can it be explained by trends in risk groups? | Q26829553 | ||
| Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis | Q28305321 | ||
| Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer | Q58279938 | ||
| Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri | Q73721770 | ||
| High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer | Q83784129 | ||
| Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study | Q85026546 | ||
| Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Q29620303 | ||
| Human papillomavirus-related disease in people with HIV | Q33425662 | ||
| Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis | Q33883532 | ||
| Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus | Q33961947 | ||
| Human papillomavirus type 16 DNA in anal cancers from six different countries | Q34393779 | ||
| Sexually transmitted infection as a cause of anal cancer | Q34445094 | ||
| Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America | Q34635523 | ||
| Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. | Q34686633 | ||
| The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study | Q35001786 | ||
| Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses | Q35786054 | ||
| A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer | Q36069045 | ||
| A review of clinical trials of human papillomavirus prophylactic vaccines | Q36259403 | ||
| Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. | Q37003406 | ||
| Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction | Q37695507 | ||
| Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer | Q38447049 | ||
| Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. | Q39763457 | ||
| Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer | Q42204969 | ||
| One lesion, one virus: individual components of high-grade anal intraepithelial neoplasia in HIV-positive men contain a single HPV type | Q42242177 | ||
| Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva | Q42281397 | ||
| Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer | Q43596600 | ||
| The epidemiology of anal cancer | Q44520900 | ||
| Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 | ||
| Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. | Q45970323 | ||
| Signature patterns of human papillomavirus type 16 in invasive anal carcinoma | Q46830135 | ||
| Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication | Q47860026 | ||
| Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. | Q51171929 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 98-107 | |
| P577 | publication date | 2014-05-30 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide | |
| P478 | volume | 136 |
| Q57466459 | Q57466459 |
| Q57466732 | Q57466732 |
| Q38586257 | 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. |
| Q49687633 | 9-Valent human papillomavirus vaccine: a review of the clinical development program |
| Q37160661 | A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. |
| Q40632740 | A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. |
| Q36117959 | Anal Cancer Incidence in the United States, 1977-2011: Distinct Patterns by Histology and Behavior |
| Q47592792 | Anal Cancer Risk Among People With HIV Infection in the United States |
| Q35553220 | Anal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi'an, China |
| Q91955544 | Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors |
| Q58590705 | Anal cancer in high-income countries: Increasing burden of disease |
| Q54228266 | Anal cytological lesions and HPV infection in individuals at increased risk for anal cancer. |
| Q34058759 | Analytic and clinical performance of cobas HPV testing in anal specimens from HIV-positive men who have sex with men. |
| Q38372521 | Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. |
| Q35203345 | Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with men |
| Q37359575 | Burden of Cancers Attributable to Infectious Agents in Nigeria: 2012-2014. |
| Q95729310 | Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58 |
| Q60925276 | Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea |
| Q42690795 | Cancer incidence in Germany attributable to human papillomavirus in 2013. |
| Q58694386 | Cancers Due to Infection and Selected Environmental Factors |
| Q44863515 | Carcinogenic human papillomavirus infection |
| Q37456554 | Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma |
| Q40264939 | Comparison of anal HPV natural history among men by country of residence: Brazil, Mexico, and the United States. |
| Q89616801 | Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study |
| Q90485235 | Competing mortality in oropharyngeal carcinoma according to human papillomavirus status |
| Q100407296 | Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer |
| Q92714674 | Detection and genotyping of human papillomavirus virus (HPV): a comparative analysis of clinical performance in cervical and urine samples in Chilean women |
| Q42696943 | Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study |
| Q38755899 | Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing |
| Q35962276 | Diversity of human papillomavirus in the anal canal of men: the HIM Study |
| Q28603888 | Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes |
| Q54210245 | Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. |
| Q47264132 | Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. |
| Q91855004 | Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study |
| Q55293654 | Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine. |
| Q58713772 | Epidemiological and economic burden of potentially HPV-related cancers in France |
| Q98237687 | Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe |
| Q94018761 | Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation |
| Q37747827 | Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe |
| Q38682763 | Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine |
| Q97426262 | Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries |
| Q40050396 | Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial |
| Q35908027 | HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients |
| Q37705703 | HPV disease transmission protection and control |
| Q64106053 | HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report |
| Q46355059 | HPV vaccination of immunocompromised hosts |
| Q46902171 | HPV-FASTER: broadening the scope for prevention of HPV-related cancer |
| Q35598917 | HPV-induced anal lesions |
| Q37373121 | HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus. |
| Q26770541 | Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies |
| Q40170982 | Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands |
| Q36551174 | High-risk human papillomavirus cervical infections among healthy women in Guadeloupe |
| Q38657540 | Hospitalizations associated with malignant neoplasia and in situ carcinoma in the anus and penis in men and women during a 5-year period (2009-2013) in Spain: An epidemiological study |
| Q47852743 | How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. |
| Q37208823 | Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan |
| Q90284016 | Human papillomavirus (HPV) 16 infection is not detected in rectal carcinoma |
| Q38268622 | Human papillomavirus (HPV) insertional mutation as a dynamic & specific tumour biomarker in HPV-associated carcinoma |
| Q28069930 | Human papillomavirus and gastrointestinal cancer: A review |
| Q38979260 | Human papillomavirus infection and p16 overexpression in oropharyngeal squamous cell carcinoma: a case series from 2010 to 2014. |
| Q47439863 | Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis |
| Q91927364 | Immunogenicity and safety of human papillomavirus vaccine coadministered with other vaccines in individuals aged 9-25 years: A systematic review and meta-analysis |
| Q40767571 | Immunogenicity and safety of the 9-valent HPV vaccine in men. |
| Q33602635 | Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men. |
| Q26745696 | Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience |
| Q38673370 | Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials |
| Q64111789 | Incidence and time trends of anal cancer among people living with HIV in Australia |
| Q39241651 | International trends in anal cancer incidence rates |
| Q35756579 | Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions |
| Q51409399 | Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway. |
| Q35963650 | Low- and high-risk human papillomavirus genotype infections in intra-anal warts in HIV-positive men who have sex with men. |
| Q55515112 | Low-Cytotoxicity Fluorescent Probes Based on Anthracene Derivatives for Hydrogen Sulfide Detection. |
| Q41612137 | Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions |
| Q64259900 | Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016 |
| Q36745242 | Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis |
| Q93079992 | Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population |
| Q50195807 | Nine-valent human papillomavirus vaccine: great science, but will it save lives? |
| Q91839708 | Nuclear factor I X is a recurrent target for HPV16 insertions in anal carcinomas |
| Q35166924 | Papillomaviruses: Viral evolution, cancer and evolutionary medicine |
| Q52905730 | Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. |
| Q47614729 | Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance |
| Q37080479 | Prevalence of Anal HPV Infection Among HIV-Positive Men Who Have Sex With Men in India |
| Q46742595 | Prevalence of and risk factors for anal HPV among a sample of predominantly black men who have sex with men in Houston, Texas |
| Q52727914 | Prevalence of and risk factors for anal high-risk HPV among HIV-negative and HIV-positive MSM and transgender women in three countries at South-East Asia. |
| Q37135065 | Prophylactic HPV vaccination and anal cancer |
| Q40083252 | Racial Disparity in Gastrointestinal Cancer Risk |
| Q30300329 | Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica |
| Q41934682 | Role of Viruses in Gastrointestinal cancer |
| Q40978763 | Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. |
| Q49206733 | Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. |
| Q30238649 | Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches |
| Q45934714 | Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. |
| Q38630813 | Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). |
| Q48312002 | The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada |
| Q26799584 | The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa |
| Q60960084 | The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients |
| Q50544836 | The burden of HPV associated cancers in two regions in Nigeria 2012-2014. |
| Q41079680 | The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis |
| Q47368302 | Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015. |
| Q40046649 | Tumour virus vaccines: hepatitis B virus and human papillomavirus. |
| Q36817074 | US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines |
Search more.